REFERENCES
- Rosenberg S D, Goodman L A, Osher F C, et al. Prevalence of HIV, hepatitis B, and hepatitis C in people with severe mental illness. American Journal of Public Health 2001; 91: 31
- Ellen S, Devlin H, Aizenstros J, et al. HIV, Hepatitis B and C virus screening among psychiatry inpatients. Abstracts from the RANZCP 38th Congress Mutual Interests, 12–15 May 2003, Hobart, Tasmania. Australian and New Zealand Journal of Psychiatry 2003; 37(Suppl. 1)A21
- Dore G, Grulich A, Hoy J, et al. HIV/Viral Hepatitis A Guide for Primary Care, revised edn. Australasian Society for HIV Medicine, Sydney 2004
- Chou R, Clark E, Helfand M. Screening for hepatitis C virus infection: a review of the evidence for the U.S. preventive services task force. Annals of International Medicine 2004; 140: 465–479
- Crone C, Gabriel G M. Comprehensive review of hepatitis C for psychiatrists: risks, screening, diagnosis, treatment, and interferon-based therapy complications. Journal of Psychiatric Practice 2003; 9: 93–110
- Meyer J. Prevalence of hepatitis A, hepatitis B, and HIV among hepatitis Cseropositive state hospital patients: results from oregon state hospital. Journal of Clinical Psychiatry 2003; 64: 540–545
- Rodger A J, Jolley D, Thompson S C, Lanigan A, Crofts N. The impact of diagnosis of hepatitis C virus on quality of life. Hepatology 1999; 30: 1299–1301
- Turpeinen P, Leinikki P, Seppala T, et al. Drug abuse and viral hepatitis among psychiatric admissions to a Finnish psychiatric emergency ward. Nordic Journal of Psychiatry 1999; 53: 141–145
- Yovtcheva S P, Rifai M A, Moles J K, Van der Linden B J. Psychiatric comorbidity among hepatitis C-Positive patients. Psychosomatics 2001; 42: 411–415
- National Centre in HIV Epidemiology and Clinical Research. HIV/AIDS: Viral Hepatitis and Sexually Transmissible Infections in Australia Annual Surveillance Report 2003. The University of New South Wales, Sydney, NSW 2003
- Davidson S, Judd F, Jolley D, Hocking B, Thompson S, Hyland B. Risk factors for HIV/AIDS and hepatitis C among the chronic mentally ill. Australian and New Zealand Journal of Psychiatry 2001; 35: 203–209
- Australian National Council on AIDS.,Hepatitis C and Related Diseases. A Model of Care for the Management of Hepatitis C Infection in Adults. Australian National Council on AIDS, Hepatitis C and Related Diseases, Sydney, NSW 2003
- Wilson J M, Jungner G. Principles and Practice of Screening for Disease (Public Health Paper Number 34). World Health Organization, Geneva 1968
- Seymour C. Controversies in Management: screening asymptomatic people at high risk for hepatitis C. British Medical Journal 1996; 312: 1347–1348
- Edlin B R, Seal K H, Lorvick J, et al. Is it justifiable to withhold treatment for hepatitis C from illicit-drug users?. New England Journal of Medicine 2001; 345: 211–215
- Ompad D C, Fuller C M, Vlahov D, Thomas D, Strathdee S A. Lack of Behavior Change among IDUs after HCV Infection. Clinical Infectious Disease 2002; 35: 783–788
- Brunette M F, Drake R E, Marsh B J, Torrey W C, Rosenberg S D. Five-Site Health and Risk Study Research Committee. Responding to blood-borne infections among persons with severe mental illness. Psychiatric Services 2003; 54: 860–865
- Allison M, Mills P R. Controversies in management: screening asymptomatic people at high risk for hepatitis C: the case against. British Medical Journal 1996; 312: 1349–1350
- Australian Hepatitis Council. Policy Series 2: Mental Health July, 2003, Australian Hepatitis Council: http://www.hepatitisaustralia.com/PDFs/PolicySeries2.pdf. Accessed 7 October 2004
- Dore G. Sexual transmission of hepatitis C- is it a concern?. Hepatitis C Review 2003; 41: 12
- Zeuzem S. Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who responds less well?. Annals of International Medicine 2004; 140: 370–381
- Therapeutic Goods Administration. Kava Fact Sheet February, 2004, Australian Hepatitis Council: http://www.tga.gov.au/cm/kavafs0402.htm. Accessed 7 October2004
- Kidd M, Cheng W, Wilson S. Post-test counselling and initial management. Australian Family Physician (Special feature) 2003; 32: 26–29
- Rosenberg S, Brunette M, Oxman T, Marsh B, et al. The STIRR model of best practices for blood-borne disease among clients with serious mental illness. Psychiatric Services 2004; 55: 660–664
- Harley H, Shaw D, Steven I. Ongoing management of hepatitis C. Australian Family Physician (Special feature) 2003; 32: 30–35
- Sylvestre D L. Injection drug use and Hepatitis C: from transmission to treatment. Psychiatric Annals 2003; 33: 377
- Loftis J M, Hauser P. Comanagement of depression and HCV treatment. Psychiatric Annals. 2003; 33: 385
- Dieperink E, Ho S B, Thuras P, Willenbring M L. A prospective study of neuropsychiatric symptoms associated with interferon-α-2b and ribavirin therapy for patients with chronic hepatitis C. Psychosomatics 2003; 44: 104–112
- Cheung R, Ahmed A. Treating chronic hepatitis C patients with psychiatric disorders: an uphill battle. American Journal of Gastroenterology 2001; 96: 3–4
- Schaefer M, Schmidt F, Folwaczny C, et al. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology 2003; 37: 443–451
- Taylor L E, Schwartzapfel B, Allen S, Jacobs G, Mitty J. Extending treatment for HCV infection to HIV-HCV coinfected individuals with psychiatric illness and drug dependence. Clinical Infectious Diseases 2003; 36: 1501–1502
- Van Thiel D H, Friedlander L, De Maria N, Molloy P, Kania R J, Colantoni A. Treatment of chronic hepatitis C in individuals with pre-existing or confounding neuropsychiatric disease. Hepato-Gastroenterology 1998; 45: 328–330